SciELO - Scientific Electronic Library Online

vol.7 issue2Comparison of the thrombin generation potential in postpartum delivery with postpartum cesarean section. Preliminary resultsTobacco use in a population diagnosed with pulmonary tuberculosis, Uruguay - 2018 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links


Revista Uruguaya de Medicina Interna

On-line version ISSN 2393-6797


GARCIA ROJAS, Zulay Andrea; CRISTANCHO SIERRA, Diana Marcela; PEREZ PAPADOPULOS, Amalia Verónica  and  ORMAECHEA GORRICHO, Gabriela. Use of empagliflozin in type 2 diabetic patients with heart failure. Rev. Urug. Med. Int. [online]. 2022, vol.7, n.2, pp.37-45.  Epub July 01, 2022. ISSN 2393-6797.


Heart failure is a pathology with high prevalence and morbidity and mortality. Among the therapeutic strategies, addressing comorbidities should be considered, including type 2 diabetes mellitus. Patients with associated heart failure have a 75% higher risk of hospitalization and mortality. The Food and Drug Administration has emphasized since 2008 that all new hypoglycemic agents must have a beneficial or at least neutral effect at the cardiovascular level. Several studies have shown that sodium-glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) meet these requirements. The objective of this work is to describe the "real life" experience of empagliflozin in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction.


A prospective, longitudinal study was carried out between July 2019 and April 2021 in a Multidisciplinary Heart Failure Unit.


Twenty-five patients (13 men) with a mean age of 61 years were included. The target dose of empagliflozin was achieved in 95% of patients. A decrease in weight, glycosylated hemoglobin and fasting blood glucose was observed.


Empagliflozin presented good tolerability, with beneficial effects at the cardiovascular level and minimal adverse effects.

Keywords : type 2 diabetes mellitus; heart failure; sodium-glucose cotransporter type 2 inhibitors.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )